Belimumab for the Treatment of Early Diffuse Systemic Sclerosis

ConclusionPatients in both treatment groups experienced significant improvements in MRSS. The median difference was greater in the belimumab group but did not achieve statistical significance in this small pilot study. AEs were similar between the groups. Changes in gene expression were consistent with mechanism of action and showed that clinical response to treatment with belimumab is associated with a significant decrease in profibrotic genes and pathways. Additional studies are needed to determine the role of belimumab in the treatment of dcSSc.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fart.40358

Source: Arthritis and Rheumatism - December 29, 2017 Category: Rheumatology Authors: Jessica K. Gordon, Viktor Martyanov, Jennifer M. Franks, Elana J. Bernstein, Jackie Szymonifka, Cynthia Magro, Horatio F. Wildman, Tammara A. Wood, Michael L. Whitfield, Robert F. Spiera Tags: Original Article Source Type: research